You are here
ACCM meeting #17, 23 May 2017
The 17th meeting of the Advisory Committee on Complementary Medicines (ACCM), May 2017.
The meeting of the Advisory Committee on Complementary Medicines (ACCM).
At this meeting, the committee's advice was sought on a proposed maximum daily dose for cysteine, cysteine hydrochloride and cysteine hydrochloride monohydrate. The TGA proposed a maximum daily dose of 450 mg L-cysteine. This equates to 585 mg cysteine hydrochloride and 652 mg cysteine hydrochloride monohydrate.
The committee noted the European Chemicals Agency (ECHA) Derived No Effect Level (DNEL) for L-cysteine, data from the Norwegian Scientific Committee for Food Safety (VKM) evaluation and the Australia-New Zealand Food Standard 2.9.4. The committee considered that a dose restriction of 750mg cysteine for adults and 500mg cysteine for children could be appropriate.
Members
Membership comprises of professionals with specific scientific, medical, clinical expertise as well as appropriate consumer health issues relating to complementary medicines.
Outcomes
-
Meeting statementsAdvisory Committee on Complementary Medicines Meeting 17 meeting statement